ArriVent BioPharma, Inc.（AVBP）の財務AVBPArriVent BioPharma, Inc.

Evaluating the bottom line, ArriVent BioPharma, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.10%, provide a clear picture of how effectively AVBP converts its operational activities into shareholder value.

In the context of the broader market, AVBP competes directly with industry leaders such as USNA and ARTV. With a market capitalization of $1.04B, it holds a leading position in the sector. When comparing efficiency, AVBP's gross margin of N/A stands against USNA's 78.35% and ARTV's N/A. Such benchmarking helps identify whether ArriVent BioPharma, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported continuous net losses, with a net income of -49,893,000 USD in Q2 2026 and an EPS of -1.05 for the last quarter, reflecting ongoing financial struggles.